RxDoctor Payments Data

Kami Kim, MD

Infectious Disease · Tampa, FLNPI 1477638252

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,395 of the $5,716 with a category attached, or 76.9%. 4 manufacturers reported payments, led by Shionogi Inc at 44.1% of the total. 2025 is the largest year on record at $3,405, more than ten times the $63 reported in 2021.

$5,716in general payments, 2019–2025

Across 9 payments — averaging $635.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shionogi Inc$3K
  • Regeneron$2K
  • Biomerieux Inc$1K
  • Angiodynamics, Inc.$116
$2,345,390in research payments, 2019–2025

Across 299 payments — averaging $7844.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$2.2M
  • Pfizer$92K
  • Dompe Farmaceutici S.p.a.$31K
  • Astrazeneca UK Limited$27K
  • AstraZeneca$25K
  • Merck$3K
  • plus $3K from 2 others

What the payments were for

  • Consulting fees$4,39577%
  • Travel & lodging$3456%
  • Food & beverage$97617%

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Shionogi Inc1$2,520
Regeneron3$1,938
Biomerieux Inc4$1,143
Angiodynamics, Inc.1$116

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,716 in reported general payments places this provider in the 80th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$7,227
Medicare patients
34
Services billed
78

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →